Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT01880424 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01880424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01880424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2013
Completion date
May 31, 2015
Enrollment
1,722 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome with constipation (ibs-c)